Recent Quotes

My Watchlist

Indicators

Seagen Inc. - Common Stock (NQ: SGEN )

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	228.91 (1)
Ask (Size)	228.96 (22)
Prev. Close	228.74
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	181,934,500
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

3 Steal-of-a-Deal Stocks to Snap Up Right Now

February 26, 2024

Here are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now.

Via InvestorPlace

Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment

February 22, 2024

Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...

Via Benzinga

Performance

More News

Get Rich Quick with These 7 Growth Stocks to Buy Now

February 20, 2024

Via InvestorPlace

7 Dividend Stocks to Buy at a 52-Week Low

February 12, 2024

Via InvestorPlace

Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market

February 01, 2024

Via InvestorPlace

Looking Into Seagen's Recent Short Interest

December 13, 2023

Via Benzinga

Seagen Inc. (NASDAQ: SGEN) is a Leading Gainer in 12/12 Morning Trading

December 12, 2023

Via Investor Brand Network

What the Options Market Tells Us About Seagen

December 11, 2023

Via Benzinga

3 Pharma Stocks Could Be the Pills Your Portfolio Needs

January 18, 2024

Via InvestorPlace

How To Earn $500 A Month From Pfizer Stock

January 02, 2024

Via Benzinga

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024

December 29, 2023

Via Benzinga

3 Stocks That Are About to Get Absolutely Crushed

December 14, 2023

Via InvestorPlace

$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today

December 07, 2023

Via Benzinga

Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast

December 14, 2023

Via Benzinga

Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?

December 14, 2023

Via The Motley Fool

3 Sleepy Stocks Ready to Wake up in 2024

December 13, 2023

Via InvestorPlace

Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'

December 13, 2023

Via Benzinga

Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints

December 13, 2023

Via Investor's Business Daily

Why Is US Pharma Giant Pfizer Stock Trading Lower Today?

December 13, 2023

Via Benzinga

Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition

December 12, 2023

Via Benzinga

Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal

December 12, 2023

Via Benzinga

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

December 10, 2023

From Seagen Inc.

Via Business Wire

3 Blue-Chip Stocks Set to Make a Comeback in 2024

December 08, 2023

Via InvestorPlace

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

December 06, 2023

From Seagen Inc.

Via Business Wire

ImmunoGen Stock Nearly Doubled On Thursday: What Happened?

November 30, 2023

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.